Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions

Circulation

Volumn 94, Issue 9, 1996, Pages 2064-2071

  Oltrona, Luigi ^a   Eisenberg, Paul R ^b   Lasala, John M ^b   Sewall, David J ^b   Shelton, Marc E ^b   Winters, Kenneth J ^b,c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

coagulation; heparin; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; THROMBIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0029827761     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2064     Document Type: Article

References (38)

1. Ellis SG, Roubin GS, King SB, Douglas JS, Weintraub WS, Thomas RG, Cox WR. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation. 1988;77: 372-379.
2. Narins CR, Hillegrass WB, Nelson CL, Tcheng JE, Harrington RA. Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667-671.
3. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
4. Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DH, Ratner DE, Weiss MB, Hjemdahl-Monsen CE, Myler RK, Moses J, Unterecker WJ, Grunwald AM, Garrett JS, Cowley MJ, Anwar A, Sobolski J, for the TAUSA Investigators. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: results of the TAUSA trial. Circulation. 1994;90:69-77.
5. Violaris AG, Melkert R, Herrman JR, Serruys PW. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis. Circulation. 1996;93:889-897.
6. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
7. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23;1061-1065.
8. Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J. 1990;63:18-21.
9. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989;18:206-209.
10. Sugrue DD, Holmes DR, Smith HC, Reeder GS, Lane GE, Vlietstra RE, Bresnahan JF, Hammes LN, Piehler JM. Coronary artery thrombus as a risk factor for acute vessel occlusion during percutaneous transluminal coronary angioplasty: improving results. Br Heart J. 1986;56:62-66.
11. White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Shaw D, Jain SP, Bass TA, Heuser RR, Teirstein PS, Bonan R, Walter PD, Smalling RW. Coronary thrombi increase PTCA risk: angioscopy as a clinical tool. Circulation. 1996;93:253-258.
12. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
13. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation. 1985;71:912-918.
14. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.
15. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
16. Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MM. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation. 1984;70:843-850.
17. Ellis SG. Elective coronary angioplasty: technique and complications. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders Co; 1994:199-222.
18. Dehmer GJ, Sehmitz JM, Malloy CR. A new technique for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn. 1986;12:426-429.
19. Ambrose JA, Israel DH. Angiography in unstable angina. Am J Cardiol. 1991;68:78B-84B.
20. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
21. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood. 1984;64:791-796.
22. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam JY, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation. 1988;78:654-660.
23. Avendano A, Ferguson JJ. Comparison of Hemochron and Hemotec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:907-910.
24. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn. 1993;28:279-282.
25. Hillegrass WB, Brott BC, Narins CR, Haura EB, Phillips HR, Stack RS, Califf RM. Predictors of blood loss and bleeding complications after angioplasty. J Am Coll Cardiol. 1994;23:69A. Abstract.
26. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91;2882-2890.
27. Ring ME, Vecchione JJ, Fiore LD, Ruocco NA Jr, Jacobs AK, Deykin D, Ryan TJ, Faxon DP. Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Cardiol. 1991;67: 1330-1334.
28. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, Ardissino D, Ambrose JA. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol. 1994;24:1484-1491.
29. Shammas NW, Cunningham MJ, Pomerantz RM, Francis CW. Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 1994;72:672-675.
30. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb. 1992;12:1475-1487.
31. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
32. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883.
33. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
34. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
35. Tripodi A, Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost. 1994;71:605-608.
36. Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn. 1995;34:1-5.
37. Conrad Smith AJ, Gold HD, Werner W, Holt R, Fitzpatrick K, Bovill EG, Fuster V, Jang I. Transient hypercoagulable state after abrupt discontinuation of heparin in patients undergoing percutaneous coronary angioplasty. Circulation. 1993;88(suppl I):I-209. Abstract.
38. Gabliani G, Deligonul U, Kern MJ, Vandormael M. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J. 1988;116:696-700.